Item 8.01 Other Events.

On April 15, 2022, Royalty Pharma plc filed a prospectus supplement relating to up to 350,000 of its Class A ordinary shares (the "Securities") to be awarded from time to time to employees and consultants of RP Management, LLC pursuant to the RP Management Equity Incentive Plan (the "Plan"). In connection with the Plan, the Company is filing a legal opinion regarding the validity of the Securities as Exhibit 5.1 herewith.

Item 9.01. Financial Statements and Exhibits





  (d) Exhibits



 5.1              Opinion of Davis Polk & Wardwell London LLP with respect to the
                Securities.

23.1              Consent of Davis Polk & Wardwell London LLP (included in Exhibit
                5.1).

Exhibit 104     Cover Page Interactive Data File (embedded in the cover page
                formatted in Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses